In the last two decades, the availability of new disease-modifying therapies has radically changed the management of multiple sclerosis (MS) and relapsing--remitting MS in particular ([@B1]), resulting in a longer life expectancy for patients with the disease ([@B2]). Nevertheless, MS currently remains incurable and, in most patients, disability will eventually progress and they must live with the very many symptoms associated with the disease. These symptoms can have a major impact on patient\'s quality of life ([@B3]) and their management is considered important, although traditionally, this area has received far less attention than disease-modifying therapies ([@B4]).

A wide range of treatments are available to manage each of the MS symptoms ([@B5]--[@B7]). Given that different agents are used for different symptoms and a patient may have several symptoms present at the same time, many MS patients are multi-medicated, particularly as most patients will also be receiving disease-modifying therapies. This article will assess the current fragmented approaches to pharmacological management of spasticity muscle tone increase-related symptoms and their shortcomings. Given that the treatment of MS-associated muscle spasticity has been associated in a good number of clinical trials and also observational studies with the improvement of several other functions/symptoms present in MS ([@B8]), we will conceptualize, and subsequently hypothesize, about the clinical interest of introducing the more broad concept of "Spasticity-Plus Syndrome" to provide a unified framework for managing all these seemingly related functions/symptoms. By applying such a concept, it would be possible to simplify the management of symptoms associated with MS and reduce importantly the interactions and adverse effects associated with poly-medication.

MS Symptoms {#s1}
===========

MS pathology affects multiple areas of the central nervous system (CNS), producing therefore a multiplicity of symptoms that can be basically classified as sensory alterations, fatigue, importantly cognitive dysfunction, pain (both paroxysmal and persistent), visual and brainstem symptoms (diplopia, oscillopsia, facial sensory symptoms, vertigo, and dizziness, nausea and vomiting, instability, etc.), those relating to mobility (spasticity, weakness, ataxia and tremor, impaired ambulation, and hand function), psychologic/psychiatric alterations (anxiety, depression, etc.), bowel, sexual and bladder dysfunctions, sleep disorders, and paroxysmal symptoms (seizures, dysarthria, etc.). All these symptoms vary along the course of the disease, being more prevalent as the disease evolves ([Table 1](#T1){ref-type="table"}) ([@B9]--[@B12]) ([Figure 1](#F1){ref-type="fig"}).

###### 

The percentage of symptoms present in multiple sclerosis vary along the course of the disease \[adapted from ([@B9]--[@B12])\].

  **Symptom**                                                                                **% (At onset-advanced)**
  ------------------------------------------------------------------------------------------ ---------------------------
  Sensory alterations                                                                        85--94
  Fatigue                                                                                    79--96
  Cognitive dysfunction                                                                      63--81
  Pain                                                                                       57--85
  Visual and brainstem symptoms (scotoma, diplopia, oscillopsia, vertigo, dizziness, etc.)   55--92
  Motor alterations: spasticity, ataxia, tremor, impaired ambulation                         50--91
  Psychologic/psychiatric alterations (anxiety, depression, etc.)                            50--79
  Bowel alterations                                                                          41--82
  Sexual dysfunction                                                                         40--90
  Urinary dysfunction                                                                        40--87
  Sleep disorders                                                                            40--60
  Paroxysmal symptoms (seizures, dysarthria, etc.)                                           30--81

![Spasticity prevalence according to disease duration in years (*N* = 23,842). With permission ([@B9]).](fneur-11-00152-g0001){#F1}

Spasticity, a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes, due to the interruption of craniocaudal pathways by MS lesions at different CNS levels, is a very frequent symptom in patients with this disease. A large survey in the United States found 84% of patients with MS with some form of spasticity, with severity ranging from minimal (31%) to total (4%) ([@B12]). Similar results were obtained in a recent survey in the United Kingdom, which reported some form of spasticity in 86% of patients with MS ([@B13]). Another survey from the United Kingdom found that 47% of randomly selected patients with MS had clinically significant spasticity, defined as modified Ashworth scale score of 2, 3, or 4 ([@B14]). Spasticity is an important symptom of MS because it has a negative effect on mobility and can be painful ([@B15], [@B16]), which in turn is ranked highly as a concern among patients with MS and is considered to have a large impact on quality of life ([@B3], [@B17], [@B18]). Moreover, the muscle rigidity and spasms of spasticity trigger, worsen, or are associated to other functions/symptoms in MS subjects beyond mobility impairment, such as fatigue ([@B3]), sleep disorders, and bladder dysfunction ([@B19]) ([Figure 2](#F2){ref-type="fig"}).

![Symptom reduction priorities for patients. With permission ([@B18]).](fneur-11-00152-g0002){#F2}

Ataxia, reported in up to 80% of MS patients at some point in their disease ([@B20]), and tremor, detected in more than a half of subjects in a sample of randomly selected patients with MS in a British study ([@B21]), are also impairing symptoms that can impact mobility.

Bladder symptoms have been reported in approximately three-quarters of patients with MS ([@B22]), while sexual dysfunction was found to be present in 84% of men and 85% of women ([@B23]). Both types of dysfunction can have a marked impact on quality of life, including among patients with otherwise low disability ([@B24]). Bowel dysfunction (including both constipation and fecal incontinence) was reported in 68% of an unselected patient population with MS ([@B25]).

Fatigue, depression, and cognitive impairment are also highly prevalent among patients with MS and impact quality of life even after accounting for physical disability ([@B26], [@B27]). Central pain in MS can be as severe as that associated with arthritic conditions ([@B28]) and the need for treatment may be underestimated.

In summary, symptoms of MS are widespread, varied, often interlinked, and highly prevalent among patients with the disease. The impact on quality of life is substantial, and mobility is a concern for patients ([@B16], [@B17]). MS symptoms have been cited as a major barrier for employment ([@B29]). Appropriate management of these symptoms is therefore imperative.

Management of Spasticity Symptoms {#s2}
=================================

As detailed above, the symptoms of MS are varied and substantially impact patients\' well-being. Management of symptoms is, however, a complex task requiring a multidisciplinary approach. In some cases, non-pharmacological interventions may be beneficial, e.g., physiotherapy for spasticity, but might have a limited time effect and the evidence supporting such approaches is not always strong ([@B30]), and pharmacological interventions are often considered necessary. As shown in [Table 2](#T2){ref-type="table"}, a wide variety of agents can be used ([@B31], [@B32]).

###### 

Commonly used pharmacological treatments for MS symptoms \[adapted from ([@B31], [@B32])\].

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Symptom**                                               **Pharmacological treatment**
  --------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **MOBILITY-RELATED SYMPTOMS**                             

  Spasticity                                                Baclofen, tizanidine, nabiximols (THC:CBD), benzodiazepines (diazepam, clonazepam), gabapentin, dantrolene, botulinum toxin A (local treatment), intrathecal baclofen

  Ataxia and tremor                                         Propranolol, clonazepam, levetiracetam, isoniazid, carbamazepine, ondansetron, dolasetron, cannabinoids, glutethimide

  Impaired ambulation                                       Aminopyridines (fampridine)

  **BLADDER, BOWEL, AND SEXUAL DYSFUNCTION**                

  Urinary dysfunction                                       *Bladder inefficiency:* α1-blockers (indoramin)\
                                                            *Bladder overactivity:* antimuscarinics, intravesical botulinum toxin A, desmopressin, cannabinoids, intravesical vanilloids

  Bowel dysfunction                                         Bulking agents, Laxatives

  Sexual dysfunction                                        Sildenafil, tadalafil, vardenafil

  **FATIGUE, COGNITIVE IMPAIRMENT, AND MOOD DISTURBANCE**   

  Fatigue                                                   Amantadine, modafinil, pemoline, aminopyridine, carnitine

  Cognitive dysfunction                                     Acetylcholinesterase inhibitors, memantine, amantadine, pemoline, gingko biloba, L-amphetamine sulfate

  Mood disturbance                                          Fluoxetine, sertraline, moclobemide

  **PAIN**                                                  

  Paroxysmal pain                                           Carbamazepine, oxcarbazepine, lamotrigine, gabapentin, topiramate, misoprostol

  Persistent pain                                           Amitriptyline, pregabalin, gabapentin, lamotrigine, levetiracetam, cannabinoids

  **VISUAL AND BRAINSTEM SYMPTOMS**                         

  Visual dysfunction                                        Memantine, gabapentin

  Brainstem-related symptoms                                Antiepileptic drugs

  **SLEEP DISORDERS**                                       

  Excessive sleepiness\                                     Modafinil\
  Restless legs syndrome                                    Dopaminergic agonists
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Any pharmacological intervention has a risk of side effects ([Table 3](#T3){ref-type="table"}) and this risk is accentuated by drug--drug interaction possibilities. In some cases, the side effects from a drug to treat one MS symptom may exacerbate another symptom produced by the disease. For example, a number of treatments used for spasticity, fatigue, pain, and depression can all cause erectile dysfunction and decreased libido ([Table 4](#T4){ref-type="table"}) ([@B33]). An approach that would simplify the management of the diverse symptoms of MS-associated spasticity could potentially be beneficial for the patient.

###### 

Main side effects of commonly used treatments for spasticity according to the EU Summary of Product Characteristics.

  -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baclofen                   **Side effects**: depression, fatigue, ataxia, and tremor\
                             **Warnings**: Psychotic disorders, schizophrenia, depressive or manic disorders, confusional states or Parkinson\'s disease may be exacerbated by treatment\
                             **Drug--drug interactions**: muscle relaxants (such as tizanidine), with synthetic opiates or with alcohol, tricyclic antidepressants, anti-hypertensives

  Tizanidine                 **Side effects**: somnolence, dizziness, fatigue\
                             **Drug-drug interactions**: CYP inhibitors, antihypertensives, oral contraceptives

  **Nabiximols (THC**:CBD)   **Side effects**: application site reactions, dizziness, fatigue, anxiety, disorientation, rare possibility of falls\
                             **Drug--drug interactions**: CYP inhibitor (ketoconazole, fluconazole, rifampicin, carbamazepine, phenytoin, phenobarbital, St John\'s Wort), alcohol, contraceptives

  Diazepam                   **Side effects**: Confusion, drowsiness, ataxia, impaired motor ability, tremor, fatigue, withdrawal symptoms\
                             **Drug--drug interactions**: alcohol, neuroleptics, anxiolytics/sedatives, hypnotics, antidepressants, anticonvulsants, sedating antihistamines, antipsychotics, baclofen tizanidine

  Clonazepam                 **Side effects**: Impaired concentration, restlessness, confusional state and disorientation, somnolence, slowed reaction, muscular hypotonia, dizziness, ataxia, light-headedness, co-ordination disturbances, fatigue and muscle weakness\
                             **Drug--drug interactions**: wide range of potential interactions with different classes of drug

  Gabapentin                 **Side effects**: confusion and emotional lability, depression, anxiety, nervousness, somnolence, dizziness, ataxia, convulsions, hyperkinesia, dysarthria, amnesia, tremor, insomnia, headache, coordination abnormal, nystagmus, increased, decreased, or absent reflexes, visual disturbances, diplopia, vertigo, arthralgia, myalgia, back pain, twitching, impotence, fatigue\
                             **Drug--drug interactions**: Opioids

  Carbamazepine              **Side effects**: Ataxia, dizziness, somnolence; diplopia, headache; fatigue\
                             **Drug--drug interactions**: inhibitors or inducers of CYP 3A4

  Levetiracetam              **Side effects**: Depression, hostility/aggression, anxiety, insomnia, nervousness/irritability, somnolence, headache, convulsion, balance disorder, dizziness, lethargy, tremor, asthenia/fatigue\
                             **Drug--drug interactions**: anti-epileptic medications

  Dantrolene                 **Side effects**: depression, confusion, insomnia, nervousness; seizure, visual disturbances, speech disturbances, headache\
                             **Drug--drug interactions**: non-depolarizing muscle relaxants

  Botulinum toxin A          **Side effects**: Somnolence, gait disturbance, paresthesia (dependent on site of administration)\
                             **Drug--drug interactions**: Potentially with agents with neuromuscular blocking effects
  -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Adverse sexual function effects of drugs used in the symptomatic treatment of MS \[adapted from ([@B33])\].

  -------------------------------------------------------------------------------------------------------------------------------
  **Symptoms of MS**              **Treatment**                   **Adverse sexual function effects associated with treatment**
  ------------------------------- ------------------------------- ---------------------------------------------------------------
  Cognitive dysfunction           Donepezil                       N/A

  Spasticity                      Baclofen\                       ED, inability to ejaculate (rare)\
                                  Tizanidine\                     Urinary frequency, urgency, incontinence,\
                                  Dantrolene\                     urinary retention\
                                  Clonidine\                      Decreased libido, ED, retrograde ejaculation\
                                  Benzodiazepines                 N/A\
                                                                  N/A

  Fatigue                         Amantadine\                     Decreased libido\
                                  Modafinil\                      N/A\
                                  Methylphenidate\                N/A\
                                  Amphetamine/dextroamphetamine   ED, changes in libido (dose dependent)

  Pain                            Tricyclic antidepressants\      ED, ejaculatory impairment, anorgasmia,\
                                  \                               decreased libido\
                                  Valproic acid\                  ED\
                                  Carbamazepine\                  ED\
                                  Oxcarbazepine\                  N/A\
                                  Lamotrigine\                    ED\
                                  Gabapentin\                     N/A\
                                  Duloxetine                      Decreased libido, ED, ejaculation\
                                                                  dysfunction and anorgasmia

  Bladder and bowel dysfunction   Anticholinergic medication      Dry mouth, vaginal dryness, constipation

  Depression                      SSRIs\                          Decreased libido, anorgasmia, delayed ejaculation\
                                  \                               N/A\
                                  Bupropion\                      ED, anorgasmia
                                  Venlafaxine                     
  -------------------------------------------------------------------------------------------------------------------------------

*ED, erectile dysfunction; MS, multiple sclerosis; N/A, not applicable; SSRIs, selective serotonin reuptake inhibitors*.

The Broad Concept of "Spasticity-Plus Syndrome" in MS {#s3}
=====================================================

A syndrome in medicine is classically defined as a combination of signs and/or symptoms that forms a distinct clinical picture indicative of a particular disease or disorder ([@B34]). Usually, these signs and/or symptoms would be considered to have a common underlying pathophysiology, or respond to a given therapy, although the clinical manifestations could be varied. In MS, spasticity is thought ultimately to arise from damage to motor areas or pathways, at multiple possible levels, in the CNS, leading to dynamic changes in motor circuit function and muscle tone that affect neuronal circuits and thereby cause spasticity ([@B35]). Bladder dysfunction in MS is originally caused by damaged neural pathways between the pons and sacral spinal cord, in turn impairing bladder function ([@B36]). Likewise, progressive demyelination and axonal or neuronal damage of the CNS leads to fatigue ([@B37]) and cognitive impairment ([@B28]). The presence of spasticity has been associated with worsening of other functions/symptoms in an epidemiological study of spasticity in MS (spasms, pain, bladder dysfunction, and sleep alterations) ([@B3], [@B19]) ([Figure 3](#F3){ref-type="fig"}).

![Areas of the CNS mediating spasticity.](fneur-11-00152-g0003){#F3}

Although the specific mechanisms of the above symptoms might vary, damage to the CNS is common to all of them and we could consider, for practical reasons, as forming part of a syndrome, in which we would denote this new broad "Spasticity-Plus Syndrome" as a useful concept to be used in the symptomatic management in MS. This could be considered as an extension of the definition of symptom clusters or complexes, which underscores two primary features that have been defined as the existence of "three or more symptoms (e.g., pain, fatigue, sleep insufficiency) that are related to each other and that the symptoms must be inter-related through a common etiology or statistically as a cluster or latent variable. Such concurrent symptoms likely have a synergistic influence on behavioral, functional, and QOL outcomes and co-occurring symptoms seemingly provide a more efficient target for management than a single, isolated symptom taken out of its clinical context" ([@B38]).

The framing of MS symptoms within a syndrome also implies that a single intervention, in this case one that targets the cannabinoid system, a widely distributed molecular system in the CNS, may potentially influence a range of different symptoms. The presence in MS patients of one or more of the symptoms contained in the broad "Spasticity-Plus Syndrome" concept (spasticity and/or spasms-cramps and/or pain and/or bladder dysfunction and/or sleep disorders and/or fatigue and/or tremor) would have to trigger in physicians the search of the other symptoms\' presence and severity and the attempt to manage them as appropriately as possible with proven, well-tolerated, and as simple as possible to use options.

The cannabinoid system is present in the brain, spinal cord, and peripheral nerves and comprises the cannabinoid receptors, CB~1~ and CB~2~, along with their ligands, the endocannabinoids, which are derived from fatty acids ([@B39], [@B40]). CB~1~ receptors are widely distributed within the CNS on nerve terminals, including areas associated with movement, postural control, pain and sensory perception, memory, cognition, emotion, appetite, and autonomic and endocrine function. A particularly high accumulation of CB~1~ and CB~2~ receptors is found in the brainstem where important functions/symptoms such as spasticity, sleep, bladder, and pain are mediated ([@B41]). CB~2~ receptors are mainly involved in regulating cytokine release from immune cells and immune cell migration in a manner that appears to reduce inflammation and certain kinds of pain ([@B42]). In short, the possible new and broad concept of "Spasticity-Plus Syndrome" in MS may point us toward an approach for simplifying management of MS symptoms ([Figure 4](#F4){ref-type="fig"}).

![Distribution of cannabinoid receptors (CB1 and CB2) in the central nervous system (The Endocannabinoid System). Redrawn from <https://www.fundacion-canna.es/en/endocannabinoid-system>. Accessed April 06, 2019). With permission.](fneur-11-00152-g0004){#F4}

Cannabinoids for the Treatment of Functions/Symptoms Belonging to the Broad "Spasticity-Plus Syndrome" {#s4}
======================================================================================================

Several randomized clinical trials have demonstrated improvement in resistant spasticity symptoms, in patients with MS following add-on treatment with an oromucosal spray containing a 1:1 mixture of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) ([@B43]--[@B47]).

This benefit for spasticity has also been reported in very many observational trials in the clinical practice setting ([@B48]). Studies of THC:CBD for the treatment of MS symptoms, other than spasticity itself, are fewer and often beset with design limitations, such as small number of patients. Nevertheless, large THC:CBD studies that collected evolution of pain, sleep disorders, and bladder dysfunction as secondary endpoints do point to a potential benefit for these symptoms ([@B43]--[@B46]). A substudy of the ***CA**nnabinoids for treatment of spasticity and other symptoms related to* ***M**ultiple* ***S**clerosis* study ("CAMS") ([@B49]) found significant benefit in the control of incontinence, although THC-only tolerability profile is less interesting than the THC and CBD combination ([@B50], [@B51]). In the case of MS-associated pain, a systematic review of randomized clinical trials of cannabinoid treatments concluded that these agents are effective in alleviating pain ([@B52]). There is thus evidence that THC:CBD can be used to treat a variety of MS spasticity-associated and somehow related symptoms ([@B53]). Moreover, application of the possible new broad concept of "Spasticity-Plus Syndrome" in MS would suggest an appropriate line of investigation, in patients with more than one symptom that could be amenable to a single therapy, to simplify symptom management.

As a clear limitation, we consider this as a preliminary conceptual proposal that has to be sustained in the future with new studies, not yet available, and that could give more background and support to our concept, so that the hypothesis would be testable and be a promising area of research in the field of symptomatic therapy. Another limitation is the fact that we do not know whether this concept could be applied to the spasticity present in other diseases such as spinal cord injury, stroke, etc., as it has not been surveyed yet as far as we know.

Conclusions {#s5}
===========

The numerous and varied symptoms associated with MS requires complex management with multiple drugs, all with potential side effects that may exacerbate other symptoms and with potential drug--drug interactions. Recognition that a good number of MS symptoms might have a common or close underlying pathophysiology, or respond to a single therapy, in the form of a new broad "Spastic-Plus Syndrome" in MS may help simplify treatment of these symptoms with agents such as cannabinoids that target CB~1~ and CB~2~ receptors.
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